Lv3
330 积分 2025-02-08 加入
OA06.01 A First-In-Human Phase 1 Study of SHR-4849 (IDE849), a DLL3-Directed Antibody-Drug Conjugate, in Relapsed SCLC
21天前
已关闭
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas
22天前
已完结
MA11.01 Phase 1 Study of DLL3-Targeted CAR-T Cells Armored With dnTGFBR2 in Small-Cell Lung and Large-Cell Neuroendocrine Cancers
1个月前
已关闭
Guidelines for T cell nomenclature
4个月前
已完结
皖公网安备34019202002308
